Response of Continuous Recombinant Antithrombin Infusion in Postcardiotomy ECMO Patients

Summary

The objective of this study will be to prospectively evaluate the response of a continuous infusion of recombinant human antithrombin concentrate (rhAT) (ATRYN®) to achieve and maintain the AT activity within a specified range in adult patients that require extracorporeal membrane oxygenation (ECMO) following cardiopulmonary bypass (CPB) and cardiac surgery.

Timeline

Start

2018-06-01

Primary completion

2019-06

Completion

2019-06

Drugs

Indications